Cai et al. (2025) demonstrated that CD44-targeted micelles (mP6/Rg3), composed of the CD44-binding peptide P6 and ginsenoside Rg3, exerted potent therapeutic effects against oral cancer stem cells (CSCs). The gene discussed is CD44; the disease is lip and oral cavity carcinoma.